Auxilium Biotechnologies Initiates Clinical Trial for Innovative Nerve Regeneration Device
SAN DIEGO–Auxilium Biotechnologies, a leader in regenerative medicine, has announced the enrollment of the first patient in its Neurospan-1 clinical trial. The trial is evaluating the safety and efficacy of NeuroSpan Bridge™, an investigational device designed to improve nerve regeneration in patients with nerve injuries.
The NeuroSpan Bridge™ is engineered to organize nerve regeneration by guiding axons along the same path as they bridge the injury site. This innovative technology has the potential to restore motor and sensory function while reducing complications associated with current treatments, such as chronic pain.
“We’ve spent years developing a technology with the potential to change lives, and today, we are one step closer to making that a reality,” said Jacob Koffler, PhD, MBA, CEO of Auxilium Biotechnologies. The clinical trial aims to enroll 80 patients across the United States and will assess the device’s performance, safety profile, and potential benefits over existing treatment options.
This development represents a significant milestone for Auxilium Biotechnologies, demonstrating its commitment to improving patient care through scientific excellence and innovation. The company’s expertise in regenerative science, biomaterials, and medical device manufacturing has culminated in this groundbreaking technology.
For more information about the clinical trial, please visit https://auxiliumbio.com.
About Auxilium Biotechnologies
Auxilium Biotechnologies is a pioneering biotechnology company dedicated to developing innovative solutions for traumatic injuries to the nervous system. With a focus on innovation and collaboration, the company develops cutting-edge bioprinting solutions and implantable medical devices to improve lives worldwide.
